SCHEMBL6791900

SCHEMBL6791900

CC(C)(C)OC(=O)N1CCC(Oc2ccc(-c3ccc(F)cc3)cn2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 13/20 0.61
MMP13 P45452 1/20 0.49
LIPE Q05469 1/20 0.48
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48
PTPN6 P29350 1/20 0.48
CACNB4 O00305 2/20 0.48
CACNA1A O00555 2/20 0.48
CACNA1G O43497 2/20 0.48
CACNG3 O60359 2/20 0.48
CACNA1F O60840 2/20 0.48
CACNA1H O95180 2/20 0.48
CACNB3 P54284 2/20 0.48
CACNA2D1 P54289 2/20 0.48
CACNG7 P62955 2/20 0.48
CACNA1B Q00975 2/20 0.48
CACNA1D Q01668 2/20 0.48
CACNB1 Q02641 2/20 0.48
CACNG1 Q06432 2/20 0.48
CACNB2 Q08289 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2775443 0.91 GPR119 (0.66) GPR119LIPE
Formic Acid Methyl Ester SCHEMBL30740741 0.85 GPR119 (0.62) GPR119LIPECACNB4CACNA1ACACNA1G
SCHEMBL28668694 0.84 GPR119 (0.58) GPR119LIPE
SCHEMBL18089521 0.84 GPR119 (0.58) GPR119LIPE
SCHEMBL14545549 0.84 GPR119 (0.52) GPR119MMP13CACNB4CACNA1ACACNA1G
SCHEMBL31748202 0.83 GPR119 (0.67) GPR119
SCHEMBL13993542 0.83 GPR119 (0.67) GPR119
SCHEMBL30785431 0.82 GPR119 (0.63) GPR119LIPE
SCHEMBL2775124 0.82 GPR119 (0.63) GPR119LIPE
SCHEMBL3180265 0.82 GPR119 (0.66) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040266764-A1 Hydroxamic acid derivatives HANNAH DUNCAN ROBERT 2004-12-30 US disclosed
US-6809100-B2 2-(4-(4-FURAN-2-YLPHENYL)PIPERAZINE-1-SULFONYLMETHYL)-N-HYDROXY -3-METHYLBUTYRAMIDE, FOR EXAMPLE; TREATMENT OF CANCER, INFLAMMATION, OR AN AUTOIMMUNE, INFECTIOUS OR OCULAR DISEASE DARWIN DISCOVERY LTD. (GB) 2004-10-26 US disclosed
US-6787536-B2 A HYDROXAMIC ACID COMPOUND CONTAINING HETEROAROMATIC RING ATTACHED TO SULFONYL GROUP THROUGH NITROGEN ATOM, INHIBITOR OF MATRIX METALLOPRETEINASE, USEFUL FOR TREATING DEGENERATIVE DISEASES AND CERTAIN CANCER DARWIN DISCOVERY LIMITED (GB) 2004-09-07 US disclosed
US-20030216404-A1 Hydroxamic acid derivatives HANNAH DUNCAN ROBERT (GB) 2003-11-20 US disclosed
EP-1282614-B1 HYDROXAMIC ACID DERIVATIVES DARWIN DISCOVERY LTD (GB) 2003-11-12 EP disclosed
EP-1282614-A1 HYDROXAMIC ACID DERIVATIVES Darwin Discovery Limited (GB) 2003-02-12 EP disclosed
US-20020037900-A1 Hydroxamic acid derivatives DARWIN DISCOVERY LIMITED (GB) 2002-03-28 US disclosed
WO-2001087870-A1 HYDROXAMIC ACID DERIVATIVES DARWIN DISCOVERY LIMITED (GB) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037900-A1 Hydroxamic acid derivatives ADAM17, ADAM10, ADAM33 GPR119 4313/4885MMP13 29/4885LIPE 1746/4885
US-20030216404-A1 Hydroxamic acid derivatives ADAM17, ADAM10, ADAM33 GPR119 4313/4885MMP13 29/4885LIPE 1746/4885
US-20040266764-A1 Hydroxamic acid derivatives ADAM17, ADAM10, ADAM33 GPR119 4313/4885MMP13 29/4885LIPE 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.